Longboard Pharmaceuticals Inc (LBPH) Forecast, Price Target & Analyst Ratings
NASDAQ:LBPH • US54300N1037
59.98 USD
+0.02 (+0.03%)
At close: Nov 29, 2024
60.01 USD
+0.03 (+0.05%)
After Hours: 11/29/2024, 7:46:54 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for Longboard Pharmaceuticals Inc (LBPH).
Forecast Snapshot
Consensus Price Target
$65.96
+ 9.97% Upside
Next Earnings Forecast
Release DateN/A
PeriodQ4 / 2024
EPS Estimate-$0.64
Revenue Estimate
ChartMill Buy Consensus
75.38%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$65.96
Upside
+ 9.97%
From current price of $59.98 to mean target of $65.96, Based on 13 analyst forecasts
Low
$60.60
Median
$61.20
High
$84.00
Price Target Revisions
1 Month
0.00%
3 Months
2.18%
Price Target Summary
13 analysts have analysed LBPH and the average price target is 65.96 USD. This implies a price increase of 9.97% is expected in the next year compared to the current price of 59.98.
The average price target has been revised upward by 2.18% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
75.38%
LBPH was analyzed by 13 analysts. The buy percentage consensus is at 75. So analysts seem to be have mildly positive about LBPH.
In the previous month the buy percentage consensus was at a similar level.
LBPH was analyzed by 13 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-10-15 | Truist Securities | Downgrade | Buy -> Hold |
| 2024-10-15 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2024-10-14 | Cantor Fitzgerald | Downgrade | Overweight -> Neutral |
| 2024-10-14 | B. Riley Securities | Downgrade | Buy -> Neutral |
| 2024-09-18 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-09-17 | Wedbush | Maintains | Outperform -> Outperform |
| 2024-09-16 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-09-10 | Truist Securities | Initiate | Buy |
| 2024-08-26 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2024-08-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-05 | B. Riley Securities | Maintains | Buy -> Buy |
| 2024-08-02 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-08-02 | Wedbush | Maintains | Outperform -> Outperform |
| 2024-08-02 | Citigroup | Maintains | Buy -> Buy |
| 2024-08-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-11 | Baird | Maintains | Outperform -> Outperform |
| 2024-07-02 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2024-07-02 | Citigroup | Maintains | Buy -> Buy |
| 2024-06-20 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-06-20 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2024-06-11 | B. Riley Securities | Maintains | Buy -> Buy |
| 2024-06-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-03 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-05-03 | Wedbush | Maintains | Outperform -> Outperform |
Next Earnings Forecast Details
Next Earnings Details
Release DateN/A
PeriodQ4 / 2024
EPS Estimate-$0.64
Revenue Estimate
Revenue Q2QN/A
EPS Q2Q-3.17%
Number of Analysts9
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
-1.15%
EPS (3 Months)
-24.01%
Next Earnings Summary
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A 3,203.35% | N/A 299.40% | N/A 94.41% | N/A 41.12% | N/A 89.00% | |||||
| EBITDA YoY % growth | N/A | -27.84M | -44.79M -60.88% | -56.754M -26.71% | N/A -69.66% | N/A -35.91% | N/A -20.65% | N/A 60.14% | N/A 169.21% | N/A 396.72% | N/A | N/A | |
| EBIT YoY % growth | -14.4M | -27.84M -93.33% | -44.8M -60.92% | -56.759M -26.69% | N/A -75.49% | N/A -31.79% | N/A -19.69% | N/A 12.75% | N/A 90.92% | N/A 1,273.61% | N/A 80.67% | N/A 87.89% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | -2.15 | -2.57 -19.53% | -2.38 7.39% | N/A 4.61% | N/A -26.89% | N/A -11.47% | N/A -8.21% | N/A 41.78% | N/A 93.78% | N/A 1,789.62% | N/A 278.73% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.64 -3.17% | -0.70 -65.63% | -0.72 -28.96% | -0.72 -14.30% | -0.74 -15.44% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | -26.826M -72.32% | -20.263M -11.90% | N/A | N/A | N/A |
| EBIT Q2Q % growth | -28.412M -82.44% | -31.722M -75.16% | -33.316M -29.92% | -34.655M -23.22% | -37.243M -31.08% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-10.50%
EPS Next 5 Year
2.83%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
-40.09%
EBIT Next 5 Year
22.50%
Longboard Pharmaceuticals Inc / LBPH Forecast FAQ
Can you provide the average price target for Longboard Pharmaceuticals Inc stock?
13 analysts have analysed LBPH and the average price target is 65.96 USD. This implies a price increase of 9.97% is expected in the next year compared to the current price of 59.98.
What are the consensus estimates for LBPH stock next earnings?
The consensus EPS estimate for the next earnings of Longboard Pharmaceuticals Inc (LBPH) is -0.64 USD and the consensus revenue estimate is 0 USD.
What is the number of analysts for LBPH stock?
The number of analysts covering Longboard Pharmaceuticals Inc (LBPH) is 13.